AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it has submitted a plan advising the NYSE Amex of the actions it has taken and will take to bring the Company into compliance with certain listing standards of the NYSE Amex by February 17, 2012.
The plan was submitted to the NYSE Amex on September 16, 2010 in response to a previous notification that the Company was not in compliance with the continued listing standards of Section 1003(a)(iii) of the NYSE Amex's Company Guide. The Company intends to issue a follow-up press release once it receives notification from the NYSE Amex as to the status of acceptance of the plan. The Company's common stock continues to be listed on the NYSE Amex under the ticker symbol "ASB."